Attached files

file filename
10-Q/A - 10-Q/A - MABVAX THERAPEUTICS HOLDINGS, INC.mbvx10qa_june302015.htm
EX-99.1 - MABVAX THERAPEUTICS, INC. GRANTED AND PENDING PATENTS AND APPLICATIONS - MABVAX THERAPEUTICS HOLDINGS, INC.ex99-1.htm
EX-10.9 - EXCLUSIVE LICENSE TO UNIMOLECULAR ANTIBODIES, DATED OCTOBER 13, 2011, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-9.htm
EX-10.1 - NON-EMPLOYEE DIRECTOR COMPENSATION POLICY - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-1.htm
EX-10.5 - EMPLOYMENT AGREEMENT, DATED JULY 21, 2014, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND PAUL MAFFUID, PH.D. - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-5.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER REQUIRED BY SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-2.htm
EX-10.4 - SECOND AMENDMENT TO THAT STANDARD INDUSTRIAL NET LEASE, DATED AUGUST 1, 2012, BY AND BETWEEN THE COMPANY AND SORRENTO SQUARE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-4.htm
EX-10.3 - FIRST AMENDMENT TO THAT STANDARD INDUSTRIAL NET LEASE, DATED MAY 6, 2010, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SORRENTO SQUARE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-3.htm
EX-10.8 - RESEARCH AND LICENSE AGREEMENT, DATED AS OF APRIL 7, 2008, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-8.htm
EX-10.6 - DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT, DATED APRIL 15, 2014, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND GALLUS BIOPHARMACEUTICALS NJ, LLC - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-6.htm
EX-10.7 - EXCLUSIVE LICENSE AGREEMENT FOR "POLYVALENT CONJUGATE VACCINES FOR CANCER" (SK#14491), DATED AS OF JUNE 30, 2008, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-7.htm
EX-10.2 - STANDARD INDUSTRIAL NET LEASE, DATED AS OF MAY 23, 2008, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SORRENTO SQUARE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-2.htm
EX-10.10 - OPTION AGREEMENT, DATED AUGUST 29, 2014, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND JUNO THERAPEUTICS, INC. - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-10.htm
EX-10.11 - SBIR CONTRACT FROM NATIONAL CANCER INSTITUTE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-11.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER REQUIRED BY SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-1.htm
Exhibit 32
 
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of MabVax Therapeutics Holdings, Inc. (the “Company”), does hereby certify, to such officer’s knowledge, that:
 
The Quarterly Report on Form 10-Q/A for the three months ended June 30, 2015 (the “Form 10-Q/A”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q/A fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: August 12, 2015
 
By:
 
    /s/ J. David Hansen
       
    J. David Hansen
       
    Chief Executive Officer
     
Date: August 12, 2015
 
By:
 
    /s/ Gregory P. Hanson
       
    Gregory P. Hanson
       
    Chief Financial Officer
 
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.